Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib Rollover Study for Participants from Pfizer-Sponsored Clinical Studies
NCT05226871Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jul 2022
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of palbociclib in breast cancer, head and neck cancer (HNC), sponsored by Pfizer. Started Jul 2022; status: active, not recruiting.
02
Drugs
palbociclib
03
Conditions
breast cancerhead and neck cancer (HNC)
Beyond the preview
Go deeper on NCT05226871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05226871.